Medtronic is spending fast in 2026. Two weeks after announcing CathWorks for up to $585M, the company dropped another $550M to acquire Scientia Vascular. That's over $1.1 billion committed to cardiovascular and neurovascular tools in roughly five weeks. Meanwhile, Insulet quietly recalled certain Omnipod 5 pods after 18 serious adverse events. The FTC blocked Alcon's acquisition of Lensar, redrawing the cataract robotics map. And the EPA proposed rolling back EtO emission limits for sterilization facilities, reigniting a debate that won't die quietly. Welcome to Issue #6 of The MedTech Minute.
Top Stories
Story 01
Another acquisition, because apparently what's MedTech without a little spending spree? On March 10, Medtronic announced a definitive agreement to acquire Scientia Vascular, a Salt Lake City company that makes guidewires and catheters for complex neurovascular procedures, for $550 million with potential earn-out payments post-close. (Source: Medtronic press release, March 10, 2026; Reuters) The deal is Medtronic's second major acquisition of 2026, following its February announcement to buy CathWorks for up to $585 million. Put them together and Medtronic has committed over $1.1 billion in five weeks to cardiovascular and neurovascular tools.
Scientia's portfolio slots directly into Medtronic's existing neurovascular business. With an estimated 12 million people suffering strokes globally each year (Source: World Stroke Organization), Medtronic is assembling the full procedural workflow: AI-guided diagnosis, physical vessel access, and therapy delivery, all from one company. The Scientia deal is expected to close in the first half of Medtronic's fiscal 2027, subject to regulatory approvals.
Why This Matters
Medtronic isn't buying one-off devices, it's acquiring the full clinical workflow. CathWorks tells the physician where the blockage is. Scientia gets them there. Medtronic's therapy devices do the rest. If you're building a point solution in cardiac or neuro, the question worth asking is: who controls the workflow around you, and are you a feature or a platform? Companies that own the complete procedural sequence command durable pricing power. Companies that own only one step get acquired, or displaced.
M&A
$550M
Neurovascular
Story 02
On March 12, Insulet issued a voluntary recall of specific lots of its Omnipod 5 insulin patch pods. The problem: a small manufacturing defect causes a tear in the internal tubing, potentially stopping insulin from being delivered properly. When a pod fails to deliver the correct dose, users face elevated blood glucose. In serious cases that leads to diabetic ketoacidosis, a life-threatening condition. Insulet has received 18 reports of serious adverse events tied to affected lots.
The recall affects approximately 1.5% of annual global Omnipod 5 production. Insulet is sending free replacement pods to affected customers and says it has already updated its manufacturing processes and quality controls. The company held its 2026 revenue growth guidance at 20-22% on a constant currency basis. Insulet's disclosure and response were handled well. But 18 serious adverse events in a device that insulin-dependent patients rely on around the clock deserves more than a footnote.
Recall
Patient Safety
Diabetes Devices
Story 03
On March 16, Alcon and Lensar officially terminated their merger agreement after the Federal Trade Commission announced it intended to challenge the acquisition. The FTC's concern: combining the two most significant players in femtosecond laser-assisted cataract surgery (FLACS) would reduce competition and raise prices for physicians and patients. The deal had been under regulatory review for nearly a year.
The story doesn't end there. Analysts at BTIG noted that Lensar has other potential acquirers, companies with far less FLACS market share, and thus far less antitrust exposure. The FTC blocking Alcon actually validated Lensar's market position. Expect a different buyer to emerge. Lensar's CEO said the company will share its updated strategic plans when it releases Q4 results on March 31.
M&A
FTC
Ophthalmology
Story 04
On March 13, the EPA proposed amendments to Biden-era emission standards for commercial ethylene oxide sterilization facilities. Roughly half of all sterile medical devices distributed in the U.S. rely on EtO sterilization, from pacemakers to surgical instruments to syringes. Industry groups and the EPA argued the 2024 rules put domestic sterilization capacity at risk. The EPA's proposal is published here.
The other side of the ledger: EtO is a known carcinogen linked to leukemia among workers and residents near facilities. Environmental groups have already signaled they'll challenge the proposal in court. AdvaMed praised it. This debate has run for years and a proposed rule won't resolve it. Watch for the public comment period and subsequent litigation.
Regulatory
Supply Chain
Manufacturing
Know someone in MedTech? Forward this to a colleague. It only takes 5 minutes and saves them from missing the week's biggest moves.
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $508.20 | ▼ 0.9% |
| SYK | Stryker | $352.60 | ▲ 1.3% |
| BDX | BD (Becton Dickinson) | $229.40 | ▲ 0.3% |
| JNJ | Johnson & Johnson | $160.40 | ▲ 0.8% |
| ABT | Abbott | $137.90 | ▼ 0.5% |
| ZBH | Zimmer Biomet | $108.40 | ▲ 1.0% |
| BSX | Boston Scientific | $103.60 | ▲ 0.7% |
| GEHC | GE HealthCare | $91.80 | ▲ 0.5% |
| MDT ★ | Medtronic | $87.30 | ▲ 3.4% |
| EW | Edwards Lifesciences | $73.10 | ▲ 0.9% |
★ Top Mover of the week (biggest % change). Sorted by stock price, highest to lowest. Data shown for illustrative purposes. Prices reflect approximate close, week of March 19, 2026.
Deep Dive
Medtronic's $1.1 Billion in Five Weeks, What the Acquisition Spree Says About Where MedTech Is Heading
Two deals in 35 days. That's not impulse buying, it's a thesis executing. On February 3, Medtronic announced it would acquire CathWorks for up to $585 million. On March 10, it followed with a $550 million agreement for Scientia Vascular. Both transactions involve tools used in cardiovascular and neurovascular procedures. Together, they signal what Medtronic's leadership has been communicating for two years: the company wants to own the complete procedural workflow, not just individual device categories.
Three things worth understanding about what's actually being built here:
- CathWorks fills the diagnosis layer in the cath lab. The CathWorks FFRangio system uses AI to calculate coronary blood flow restriction from standard angiogram images, eliminating the need for a physical pressure wire. This gives interventional cardiologists a faster read on whether a blockage actually needs stenting. Medtronic had been co-promoting this technology since 2022. Buying it converts a revenue-sharing arrangement into a proprietary asset with defensible IP. Reuters covered the CathWorks deal in February.
- Scientia fills the access layer in neuro cases. Scientia makes the guidewires and catheters that physicians use to physically navigate blood vessels in the brain during stroke procedures. That's the physical infrastructure that makes Medtronic's existing neurovascular therapy devices useful in the first place. Without reliable access tools, even the best thrombectomy device is harder to deploy. Scientia's portfolio integrates directly with Medtronic's existing product lineup. Medtronic's press release explains the strategic rationale.
- Both deals still face FTC review. The CathWorks deal requires FTC clearance, expected by end of Medtronic's fiscal 2026. Scientia is similarly pending. Given the FTC's recent blocking of Alcon-Lensar (covered above), regulatory risk is real. But neither CathWorks nor Scientia is a direct Medtronic competitor in their respective spaces, which makes the antitrust analysis more favorable than the cataract surgery situation.
The big picture: Medtronic is assembling a complete system for cardiovascular and neurovascular care. CathWorks tells you where the blockage is. Scientia gets you there. Then Medtronic's therapy devices do the work. That's a full procedure from one company. Medtronic's management has communicated that health systems increasingly prefer to buy integrated procedural platforms rather than individual device components, and that's exactly what Medtronic is now positioned to sell. (Source: Medtronic investor presentations and earnings calls)
Industry Shifts
Shift 01
Announced March 16, surgical robotics startup Vicarious Surgical is applying to move its shares to the Nasdaq and has reduced its 2026 cash burn forecast from roughly $35 million to approximately $19 million, without slowing its development timeline. The company's single-port robotic system for abdominal surgery remains on track for a system design freeze by year-end 2026. Under CEO Stephen From, Vicarious has been running leaner while protecting the technical milestones that matter. The Nasdaq move may be about capital access. The cash burn cut is the real signal: this company is focused on surviving long enough to get its robot to clinical trials.
Surgical Robotics
Capital Markets
Shift 02
Announced February 17, Danaher agreed to acquire Masimo in an all-cash deal valued at $9.9 billion. The transaction brings together one of the world's most disciplined operating companies and a business with pulse oximetry infrastructure embedded across more than 200 million patient monitors worldwide. Danaher's proven approach, buying businesses with recurring revenue and regulatory barriers to competition, applies cleanly to Masimo. The deal is expected to close in the second half of 2026, pending shareholder approval and regulatory review. This week's MASI stock performance reflects market confidence that the deal closes on schedule.
M&A
$9.9B
Patient Monitoring
Fun Fact & Trivia
Fun Fact
According to the FDA's CDRH product code database, more than 6,500 distinct medical device product codes have been registered in its classification system. (Source: FDA CDRH Product Code Database) They range from Class I devices, like tongue depressors and elastic bandages, which require no premarket clearance, all the way to Class III devices like implantable cardiac defibrillators and artificial hearts, which require full premarket approval (PMA). The same federal taxonomy that classifies a cotton swab also classifies a total artificial heart. That's one of the more quietly staggering facts about how this industry works.
MedTech Trivia
What company brought the first commercially successful continuous glucose monitor (CGM) to market in the U.S., and in what year did it receive FDA clearance?
👇 Scroll to the footer for the answer
Quick Question
What's the biggest bottleneck you're seeing in MedTech right now? Regulatory timelines? Reimbursement? Finding clinical partners? Something else entirely? Hit reply, I read every response.
Sponsor
